AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06508710
Drug: Ketamine
RxNorm normalized name: Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients randomized in this group will receive an intravenous ketamine in addition to venlafaxine for one week (on Days 1, 4 and 7)
Trial: NCT06311227
Drug: Venetoclax
RxNorm normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given PO
Trial: NCT05451290
Drug: Camrelizumab, apatinib, gemcitabine, oxaliplatin, tegafur
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Perioperative treatment: camrelizumab plus apatinib in combination with GEMOX 2-4 cycles (neoadjuvant); camrelizumab plus tegafur up to 1 year (adjuvant).
Trial: NCT06578520
Drug: Dapagliflozin
RxNorm normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 10 mg once per day, oral tablets
Trial: NCT06797544
Drug: Levofloxacin 0.5%
RxNorm normalized name: LEVOFLOXACIN 0.5% SOLN,OPH
DrugBank: Levofloxacin (DB01137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intralesional levofloxacin (5 mg/ml, 100 ml, Tavanic®, Sanofi, France) will be injected into each lesion based on its size (5 mg/cm2). The infiltration of intralesional dose will be given once weekly for up to 6 weeks. Treatment will be stopped in patients cured before 6 weeks of treatment, and patients were only asked to come for lesion assessment. A fine insulin needle will be used to infiltrate the lesion.~The lesion will be thoroughly infiltrated with the drug solution until the base will be completely blanched. Depending on the lesion size, the amount of solution required ranged from 0.2 to 4.0 ml per lesion. No local anesthesia was added. The solutions were injected intralesionally and not subcutaneously.
Trial: NCT05139225
Drug: TTI-622
RxNorm normalized name: SIRPA-IGG4-FC FUSION PROTEIN TTI-622
DrugBank: Maplirpacept (DB18441)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (-2) 0.4 mg/kg (-1) 0.8 mg/kg~(1 ) 1.2 mg/kg (2) 2 mg/kg (3) 4 mg/kg (4) 8 mg/kg (5) 12 mg/kg~The appropriate dose of TTI-622 will be administered IV over 60 minutes, however, can be extended up to 4 hours to mitigate Infusion-related reactions.
Trial: NCT05139225
Drug: Daratumumab Hyaluronidase-fihj
RxNorm normalized name: daratumumab-fihj / hyaluronidase-fihj Injection
DrugBank: Hyaluronidase (ovine) (DB00070)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daratumumab hyaluronidase-fihj SC 1800 mg days 1, 8, 15, and 22.
Trial: NCT06494904
Drug: Buprenorphine
RxNorm normalized name: Buprenorphine
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: All patients will receive 3 pills and will be observed for 2 hours post-study medication administration with repeated COWS at approximately hours 1 and 2. All participants will be given a referral for ongoing MOUD and will be discharged with a prescription for 16 mg daily of buprenorphine daily.
Trial: NCT05755204
Drug: LA-CAB
RxNorm normalized name: K-CAB
DrugBank: Tegoprazan (DB16690)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular LA-CAB for PrEP
Trial: NCT05546554
Drug: Suvorexant
RxNorm normalized name: Suvorexant
DrugBank: Suvorexant (DB09034)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5 mg (and up to 20 mg) Suvorexant given orally
Trial: NCT06226805
Drug: BB-031
RxNorm normalized name: rPDGF-BB
DrugBank: Becaplermin (DB00102)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Solution for injection
Trial: NCT06141473
Drug: Frexalimab
RxNorm normalized name: Frexalimab
DrugBank: Frexalimab (DB18926)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SAR441344 Solution for IV infusion
Trial: NCT06141473
Drug: Teriflunomide
RxNorm normalized name: Teriflunomide
DrugBank: Teriflunomide (DB08880)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Aubagio oral tablet
Trial: NCT06141473
Drug: Cholestyramine
RxNorm normalized name: Cholestyramine
DrugBank: Cholestyramine (DB01432)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral, 8 g 3 times daily for 11 days for accelerated elimination procedure (4 g 3 times daily for 11 days in case of intolerance). The teriflunomide local label should be followed.
Trial: NCT06141473
Drug: Activated charcoal
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral, 50 g every 12 hours for 11 days for accelerated elimination procedure. The teriflunomide local label should be followed.
Trial: NCT06632444
Drug: Survodutide
RxNorm normalized name: Survodutide
DrugBank: Survodutide (DB18989)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection
Trial: NCT06777758
Drug: Remimazolam
RxNorm normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Remimazolam
Trial: NCT06777758
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol dose reduction ratio
Trial: NCT06779370
Drug: Calcium Silicate
RxNorm normalized name: Calcium Silicate
DrugBank: Calcium silicate (DB13829)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Root canal filling was removed with endodontic file. Sterile paper points were placed at working length to assess antibacterial and antifungal effects before the medicament was placed. Subsequently, the root canals were chemomechanically prepared, final irrigation activation was performed, and second samples were collected in the same manner. The calcium silicate-based root canal medicament was placed in the canals, and the teeth were sealed with temporary fillings. A form was provided to evaluate the patients' postoperative pain levels over one week. At the second appointment, the medicament was removed, and third samples were collected to assess antibacterial effects. The root canal treatments of the patients were completed. The antibacterial and antifungal effects of the medicaments were evaluated using PCR, and the patients' postoperative pain levels were recorded using follow-up forms.
Trial: NCT06799351
Drug: Ozone therapy
RxNorm normalized name: ozone
DrugBank: Ozone (DB12510)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual treatment (by their oncologist or hematologist) + Ozone therapy by rectal insufflation. O3/O2 concentration progressively increased from 10 to 30 μg/ml; 40 sessions in 16 weeks.
Trial: NCT06799351
Drug: Oxygen (placebo)
DrugBank: Oxygen (DB09140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Usual treatment (by their oncologist or hematologist) + Oxygen by rectal insufflation. O3/O2 concentration = 0 μg/ml (only O2); 40 sessions in 16 weeks.
Trial: NCT05327946
Drug: BI 770371
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 770371
Trial: NCT05327946
Drug: ezabenlimab
RxNorm normalized name: Ezabenlimab
DrugBank: Ezabenlimab (DB17483)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ezabenlimab
Trial: NCT06435312
Drug: Zilucoplan
RxNorm normalized name: Zilucoplan
DrugBank: Zilucoplan (DB15636)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zilucoplan will be administered subcutaneously to pediatric study participants
Trial: NCT06257264
Drug: BG-68501
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Planned doses administered orally.
Trial: NCT06257264
Drug: Fulvestrant
RxNorm normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Standard dose administered via intramuscular injection.
Trial: NCT06257264
Drug: BGB-43395
RxNorm normalized name: BGB-DXP593
DrugBank: BGB-DXP593 (DB16357)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Planned doses administered orally.
Trial: NCT04564547
Drug: Islatravir
RxNorm normalized name: Islatravir
DrugBank: Islatravir (DB15653)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ISL capsule taken by mouth.
Trial: NCT04564547
Drug: Ulonivirine
RxNorm normalized name: Ulonivirine
DrugBank: Ulonivirine (DB18787)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ulonivirine tablet taken by mouth.
Trial: NCT04564547
Drug: Placebo to Ulonivirine
DrugBank: Ulonivirine (DB18787)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet matched to ulonivirine taken by mouth.
Trial: NCT05174221
Drug: Mezagitamab
RxNorm normalized name: Mezagitamab
DrugBank: Mezagitamab (DB16370)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-079 subcutaneous injection.
Trial: NCT06235905
Drug: NV-5138
RxNorm normalized name: NV-5138
DrugBank: NV-5138 (DB19180)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NV-5138 is a novel , orally bioavailable, activator of mTORC1
Trial: NCT05630833
Drug: Gepotidacin
RxNorm normalized name: gepotidacin
DrugBank: Gepotidacin (DB12134)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gepotidacin will be administered.
Trial: NCT05630833
Drug: Nitrofurantoin
RxNorm normalized name: Nitrofurantoin
DrugBank: Nitrofurantoin (DB00698)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nitrofurantoin will be administered.
Trial: NCT05214391
Drug: Zanubrutinib
RxNorm normalized name: Zanubrutinib
DrugBank: Zanubrutinib (DB15035)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: The initial dose is 80mg/day. If the treatment is ineffective after 4 weeks, and under the condition of good safety, the investigator will judge that the dosage should be added to 80mg twice/day，or a higher dose for oral maintenance. The maximum dose is 160mg twice a day. The duration of zanubrutinib is 24 weeks.~In case of intolerable adverse reactions, such as severe infection, severe bleeding, hematopenia, arrhythmia, etc., investigator can reduce the dose of zanubrutinib, or withdraw from clinical trials as appropriate.
Trial: NCT06323460
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT06323460
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT06323460
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given IV
Trial: NCT04777994
Drug: ABBV-CLS-484
RxNorm normalized name: Calf lung surfactant extract (CLSE)
DrugBank: Calfactant (DB06415)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral Capsule
Trial: NCT05100862
Drug: Zanubrutinib
RxNorm normalized name: Zanubrutinib
DrugBank: Zanubrutinib (DB15035)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zanubrutinib will be administered orally as two 80-milligram (mg) capsules twice a day (160 mg twice a day) or four 80-mg capsules once a day (320 mg once a day) continuously in repeated 28-day cycles.
Trial: NCT05100862
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab will be administered intravenously at a dose of 375 mg/meter squared on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. Each cycle is 28 days in length.
Trial: NCT05100862
Drug: Lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lenalidomide will be administered orally as 20-mg capsules (10 mg if creatinine clearance ≥ 30 mL/min but \< 60 mL/min) once a day on Days 1 to 21 of each 28-day cycle for a total of 12 cycles.
Trial: NCT05100862
Drug: Obinutuzumab
RxNorm normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Obinutuzumab will be administered at a dose of 1000 mg on Cycle 1 Days 1, 8, 15 and then on Cycles 2 to 6 Day 1.
Trial: NCT06630091
Drug: Golidocitinib
RxNorm normalized name: Golidocitinib
DrugBank: Golidocitinib (DB18057)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg once per day by PO
Trial: NCT06630091
Drug: Vincristine
RxNorm normalized name: Vincristine
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1.4 mg/m2 (max: 2 mg) by IV
Trial: NCT06630091
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 mg by PO
Trial: NCT06779773
Drug: Avacincaptad pegol (ACP)
RxNorm normalized name: Avacincaptad pegol
DrugBank: Avacincaptad pegol (DB15165)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravitreal injection
Trial: NCT06575530
Drug: Remimazolam Besylate
RxNorm normalized name: Remimazolam Besylate
DrugBank: Remimazolam (DB12404)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: patients will be sedated with remimazolam via intravenous pump on the day of ICU admission, the dosage will titrate with the depth of sedation evaluated with RASS. A remedial sedation protocol will be initiated if remimazolam fails to achieve a satisfactory RASS score (0 to -2 points) within its upper dosage limits, propofol will be administered intravenously at a dose of 0.2 mg, followed by reassessment 5 minutes post-injection. The same dose of propofol will be repeated if the desired sedation depth is not reached. Continuous infusion of propofol will be started at a rate of 0.2 to 1 mg/kg/h if satisfactory sedation is not attained after three consecutive intravenous injections of propofol, the continuous infusion will be discontinued once the RASS score reaching the acceptable range (0 to -2).
Trial: NCT06575530
Drug: Dexmedetomidine Hydrochloride
RxNorm normalized name: Dexmedetomidine Hydrochloride
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: patients will be sedated with dexmedetomidine hydrochloride via intravenous pump on the day of ICU admission, the dosage will titrate with the depth of sedation evaluated with RASS. A remedial sedation protocol will be initiated if dexmedetomidine fails to achieve a satisfactory RASS score (0 to -2 points) within the upper dosage limits, propofol will be administered intravenously at a dose of 0.2 mg, followed by reassessment 5 minutes post-injection. The same dose of propofol will be repeated if the desired sedation depth is not reached. Continuous infusion of propofol will be started at a rate of 0.2 to 1 mg/kg/h if satisfactory sedation is not attained after three consecutive intravenous injections of propofol, the continuous infusion will be discontinued once the RASS score reaching the acceptable range (0 to -2).
Trial: NCT05902325
Drug: Mepolizumab 100 MG Injection
RxNorm normalized name: mepolizumab 100 MG Injection
DrugBank: Mepolizumab (DB06612)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients will receive Mepolizumab 100mg SC once every 4 weeks for 48 weeks (twelve injections, no placebo) at the hospital. The IMP will be administered following clinic procedures and blood collection. Patients will be monitored at the study site for at least 30 minutes after injections for signs of hypersensitivity reaction. Subcutaneous injection sites should be alternated among the 4 quadrants of the abdomen (avoiding navel and waist areas) or the upper arms. Background therapy will be assured with mometasone furoate nasal spray (200µg BID) daily throughout the study.
Trial: NCT05704725
Drug: ABP 938
RxNorm normalized name: ABPC
DrugBank: Ampicillin (DB00415)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IVT injection
Trial: NCT05704725
Drug: Aflibercept
RxNorm normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: IVT injection
Trial: NCT06799039
Drug: Xylitol
RxNorm normalized name: Xylitol
DrugBank: Xylitol (DB11195)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Xylitol is a sugar alcohol and considered a GRAS substance by the FDA. Patients will be consecutively enrolled into one of five dosing including 1g, 2g, 5g, 7g and 9g.
Trial: NCT06381622
Drug: Ropivacaine 0.5% Injectable Solution
RxNorm normalized name: ROPivacaine 0.5% injectable solution
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 30 mL Ropivacaine 5 mg/mL (= 150 mg Ropivacaine)
Trial: NCT06381622
Drug: Ropivacaine 0.75% Injectable Solution
RxNorm normalized name: ROPivacaine 0.75% injectable solution
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20 mL Ropivacaine 7,5 mg/mL + 10 mL Lidocaine-Epinephrine (20 mg + 5 μg)/mL (= 150 mg Ropivacaine + 200 mg Lidocaine)
Trial: NCT04384367
Drug: Maxalt 10Mg Tablet
RxNorm normalized name: Maxalt 10mg Tablet
DrugBank: Rizatriptan (DB00953)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral - single dose
Trial: NCT04384367
Drug: Flanax 550mg
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral - single dose
Trial: NCT04800367
Drug: Romosozumab Prefilled Syringe [Evenity]
RxNorm normalized name: romosozumab Prefilled Syringe [Evenity]
DrugBank: Romosozumab (DB11866)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2 syringes of 105 MG/1.17 mL subcutaneous solution injected one after the other, once a month from study baseline through 11 month visit
Trial: NCT04800367
Drug: Denosumab 60 MG/ML Prefilled Syringe [Prolia]
RxNorm normalized name: denosumab 60 MG/ML Prefilled Syringe [Prolia]
DrugBank: Denosumab (DB06643)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 1 subcutaneous injection of 60 mg/mL every six months from study 12 month visit through the 24 month visit. Injections occur at the 12 and 18 month visits.
Trial: NCT04597671
Drug: Durvalumab
RxNorm normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Durvalumab is used as standard of care
Trial: NCT06138340
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will be sedated and maintained by dexmedetomidine during the surgery.
Trial: NCT06138340
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will be sedated and maintained by propofol during the surgery.
Trial: NCT06138340
Drug: Remimazolam Injection
RxNorm normalized name: remimazolam Injection
DrugBank: Remimazolam (DB12404)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will be sedated and maintained by remimazolam during the surgery.
Trial: NCT05164172
Drug: Eptinezumab
RxNorm normalized name: Eptinezumab
DrugBank: Eptinezumab (DB14040)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Concentrate for solution for infusion
Trial: NCT06162572
Drug: S095024 RDE
RxNorm normalized name: tetrahydrozoline
DrugBank: Tetryzoline (DB06764)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Via IV infusion on Day 1 of each 21-day cycle
Trial: NCT06162572
Drug: S095029 RDE
RxNorm normalized name: tetrahydrozoline
DrugBank: Tetryzoline (DB06764)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Via IV infusion on Day 1 of each 21-day cycle
Trial: NCT06162572
Drug: Cemiplimab
RxNorm normalized name: CEMIPLIMAB
DrugBank: Cemiplimab (DB14707)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 350 mg via IV infusion on Day 1 of each 21-day cycle
Trial: NCT06594939
Drug: Polatuzumab Vedotin
RxNorm normalized name: polatuzumab vedotin
DrugBank: Polatuzumab vedotin (DB12240)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: A combination of a monoclonal antibody and a chemotherapy drug.
Trial: NCT06594939
Drug: Mosunetuzumab
RxNorm normalized name: Mosunetuzumab
DrugBank: Mosunetuzumab (DB15434)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A monoclonal antibody.
Trial: NCT06594939
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Steroid, anti-inflammatory
Trial: NCT05310734
Drug: Spinosad Topical
RxNorm normalized name: spinosad topical
DrugBank: Spinosad (DB08823)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A topical suspension indicated for the treatment of scabies is used for this PK and Safety Study
Trial: NCT06635824
Drug: Acasunlimab
RxNorm normalized name: Acasunlimab
DrugBank: Acasunlimab (DB18932)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion
Trial: NCT06635824
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: IV infusion
Trial: NCT06635824
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV infusion
Trial: NCT06320041
Drug: Low dose oxelidine group
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Analgesic dose
Trial: NCT06320041
Drug: High dose oxelidine group
RxNorm normalized name: high-density polyethylene
DrugBank: Poly(lactic acid) (DB15037)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Analgesic dose
Trial: NCT06320041
Drug: Hydromorphone group
DrugBank: Hydromorphone (DB00327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Analgesic dose
Trial: NCT06531018
Drug: Eltrombopag 25 MG
RxNorm normalized name: eltrombopag 25 MG
DrugBank: Eltrombopag (DB06210)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Eltrombopag 25 mg daily and Prednisolone 1-2mg/kg, selected by block randomization from Day1 to Day 28. Both investigators and patients will be blinded.
Trial: NCT05327010
Drug: BET Bromodomain Inhibitor ZEN-3694
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT05327010
Drug: Talazoparib
RxNorm normalized name: TALAZOPARIB
DrugBank: Talazoparib (DB11760)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT04939610
Drug: 68Ga-FAP-2286
RxNorm normalized name: 68Ga-DOTATOC
DrugBank: Dotatate gallium Ga-68 (DB13925)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 68Ga-FAP-2286 IV administered as imaging agent for PET scan.
Trial: NCT04939610
Drug: 177Lu-FAP-2286
RxNorm normalized name: 177Lu-dotatate
DrugBank: Lutetium Lu 177 dotatate (DB13985)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phase 1:~Patients with positive uptake of 68Ga-FAP- 2286 will receive a fixed dose of 177Lu-FAP-2286 IV administered every 6 weeks for a maximum of 6 doses. Doses range between 3.7 and 9.25 GBq (100-250 mCi).~Phase 2:~Monotherapy: Patients with positive uptake of 68Ga FAP 2286 will receive a fixed dose of 177Lu FAP 2286 IV administered at the RP2D determined in Phase 1 dose escalation in every 4 weeks.~Combination therapy: Patients with positive uptake of 68Ga FAP 2286 will receive 177Lu-FAP-2286 based on dose escalation (starting with dose level 1) followed by dose expansion at selected dose.